Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Anat Gershoni"'
Autor:
Anat Gershoni, Ori Hassin, Nishanth Belugali Nataraj, Sivan Baruch, Adi Avioz‐Seligman, Anna Chiara Pirona, Liat Fellus‐Alyagor, Tomer Meir Salame, Saptaparna Mukherjee, Giuseppe Mallel, Yosef Yarden, Yael Aylon, Moshe Oren
Publikováno v:
Molecular Oncology, Vol 17, Iss 12, Pp 2675-2693 (2023)
The core Hippo pathway module consists of a tumour‐suppressive kinase cascade that inhibits the transcriptional coactivators Yes‐associated protein (YAP) and WW domain‐containing transcription regulator protein 1 (WWTR1; also known as TAZ). Whe
Externí odkaz:
https://doaj.org/article/2dbf7e08c0fc4450b4c84ececd4af0cb
Autor:
Ori Hassin, Nishanth Belugali Nataraj, Michal Shreberk-Shaked, Yael Aylon, Rona Yaeger, Giulia Fontemaggi, Saptaparna Mukherjee, Martino Maddalena, Adi Avioz, Ortal Iancu, Giuseppe Mallel, Anat Gershoni, Inna Grosheva, Ester Feldmesser, Shifra Ben-Dor, Ofra Golani, Ayal Hendel, Giovanni Blandino, David Kelsen, Yosef Yarden, Moshe Oren
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-15 (2022)
The differential effects of TP53 missense mutations in colorectal cancer (CRC) remain to be explored. Here the authors compare the gain of function impact of two frequent TP53 mutations in CRC and show that p53R273 mutants control a transcriptional p
Externí odkaz:
https://doaj.org/article/a119b82dad0a479ebb369694272fe374
Autor:
Saptaparna Mukherjee, Martino Maddalena, YiQing Lü, Sebastien Martinez, Nishanth Belugali Nataraj, Ashish Noronha, Sansrity Sinha, Katie Teng, Victoria Cohen-Kaplan, Tamar Ziv, Sharathchandra Arandkar, Ori Hassin, Rishita Chatterjee, Anna-Chiara Pirona, Michal Shreberk-Shaked, Anat Gershoni, Yael Aylon, Zvulun Elazar, Yosef Yarden, Daniel Schramek, Moshe Oren
Publikováno v:
Proceedings of the National Academy of Sciences. 119
Missense mutations in the p53 tumor suppressor abound in human cancer. Common (“hotspot”) mutations endow mutant p53 (mutp53) proteins with oncogenic gain of function (GOF), including enhanced cell migration and invasiveness, favoring cancer prog
Autor:
Xiaochen Sun, Randy L. Johnson, Anat Gershoni, Youngmin A. Lee, Ziv Porat, Anna P. Koh, Yujin Hoshida, Scott L. Friedman, Yael Aylon, Moshe Oren, Inbal E. Biton, Ron Rotkopf, Maria Isabel Fiel
Publikováno v:
Genes & Development. 30:786-797
The Hippo signaling pathway is a major regulator of organ size. In the liver, Hippo pathway deregulation promotes hyperplasia and hepatocellular carcinoma primarily through hyperactivation of its downstream effector, YAP. The LATS2 tumor suppressor i
Autor:
Moshe Oren, Randy L. Johnson, Ina Schmitt, Noa Furth, Vassilis G. Gorgoulis, Ron Rotkopf, Anat Gershoni, Ioannis S. Pateras, Yael Aylon, Deborah Bakaev
Publikováno v:
Molecular Cancer Research. 18:IA20-IA20
Deregulated activity of the LATS tumor suppressors has broad implications on cellular and tissue homeostasis. We examined the consequences of downregulation of either LATS1 or LATS2 in breast cancer. Consistent with their proposed tumor-suppressive r
Autor:
Anat Gershoni, Randy L. Johnson, Yael Aylon, Deborah Bakaev, Noa Furth, Elena Ainbinder, Vassilis G. Gorgoulis, Vassiliki Vlachou, Dena Leshkowitz, Ron Rotkopf, Ioannis S. Pateras, Irina Rivkin, Ina Schmitt, Moshe Oren
Publikováno v:
Life Science Alliance
In luminal B tumors LATS2 depletion results in metabolic rewiring whereas LATS1 depletion promotes the expression of basal-like features.
Deregulated activity of LArge Tumor Suppressor (LATS) tumor suppressors has broad implications on cellular
Deregulated activity of LArge Tumor Suppressor (LATS) tumor suppressors has broad implications on cellular
Publikováno v:
CNS Spectrums. 19:90-103
ObjectiveResolving the entangled nosological dilemma of whether obsessive-compulsive disorder (OCD) with and without schizophrenia (schizo-OCD and OCD, respectively) are two independent entities or whether schizo-OCD is a combined product of its pare
Autor:
Thomas A. Hopf, Ohad Tarcic, Eran Segal, Guy Goldfeld, Maya Lotan-Pompan, Odem Shani, Moshe Oren, Eran Kotler, Debora S. Marks, Anat Gershoni
Publikováno v:
Molecular Cell
Summary The TP53 gene is frequently mutated in human cancer. Research has focused predominantly on six major "hotspot" codons, which account for only ∼30% of cancer-associated p53 mutations. To comprehensively characterize the consequences of the p
Autor:
Anat Gershoni, Yael Aylon, Yujin Hoshida, Maria Isabel Fiel, Ron Rotkopf, Anna P. Koh, Randy L. Johnson, X. Sun, Moshe Oren, Scott L. Friedman
Publikováno v:
European Journal of Cancer. 61:S164